Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a promising company with a unique technology platform that has the potential to significantly improve the diagnosis and monitoring of life-altering diseases including some cancers and diseases associated with NETosis. The company's Nucleosomics platform has been validated through multiple studies, including a recent publication by Mayo Clinic demonstrating the effectiveness of Volition's Nu.Q biomarkers in trauma patients with VTE risk. While VolitionRX has faced listing and capital concerns, its recent reverse stock split and successful fundraising efforts provide a strong indication of its underlying business strength and potential for growth.

Bears say

VolitionRX is facing multiple challenges including a recent reverse stock split that could lead to decreased liquidity and negative sentiment from investors, causing further declines in market value and potential dilution of shares. Their adoption of a new liquid biopsy method has shown promising results in detecting early-stage cancers, but the company has yet to secure substantial licensing deals and will need to prove its utility in clinical decision-making. The company also faces various risks such as regulatory hurdles, competition in the liquid biopsy market, and potential legal or intellectual property disputes. It may take time for VolitionRX to stabilize and rebuild credibility with the market, so a Hold rating is recommended until there is more evidence of progress in commercialization partnerships and clear utility of their technology.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.